The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded ...

The global autoinjectors market, valued at US$1.08 billion in 2023, stood at US$1.40 billion in 2024 and is projected to advance at a resilient CAGR of 13.6% from 2024 to 2030, culminating in a ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...

Currently exempt from US tariffs, pharmaceutical manufacturers fear steep surcharges, as promised by the US president on ...

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...